AOTMiT reimbursement recommendations compared to other HTA agencies

Aneta Mela (), Dorota Lis, Elżbieta Rdzanek, Janusz Jaroszyński, Marzena Furtak-Niczyporuk, Bartłomiej Drop, Tomasz Blicharski and Maciej Niewada
Additional contact information
Aneta Mela: Medical University of Warsaw
Dorota Lis: HealthQuest Sp z o.o. Sp. K
Elżbieta Rdzanek: Medical University of Warsaw
Janusz Jaroszyński: Maria Curie-Skłodowska University of Lublin
Marzena Furtak-Niczyporuk: Medical University of Lublin
Bartłomiej Drop: Medical University of Lublin
Tomasz Blicharski: Medical University of Lublin
Maciej Niewada: Medical University of Warsaw

The European Journal of Health Economics, 2024, vol. 25, issue 8, No 1, 1310 pages

Abstract: Abstract Our objective was to compare AOTMiT (Polish: Agencja Oceny Technologii Medycznych i Taryfikacji) recommendations to other HTA (Health Technology Assessment) agencies for newly registered drugs and new registration indications issued by the European Medicines Agency between 2014 and 2019. The study aims to assess the consistency and justifications of AOTMiT recommendations compared to that of other HTA agencies in 11 countries. A total of 2496 reimbursement recommendations published by 12 HTA agencies for 464 medicinal products and 525 indications were analyzed. Our analysis confirmed that the Polish AOTMiT agency seems to bear the closest resemblance to the corresponding HTA agencies from Canada (CADTH) and New Zealand (PHARMAC), when it comes to the outcome of HTA recommendations (positive or negative). Poland had a general scheme for justifying recommendations, similar to that of Ireland—four aspects (i.e., clinical efficacy, safety profile, cost-effectiveness, and impact on the payer’s budget) are important for Poland when formulating the final decision. Compared to other countries, Poland shows a noticeably different pattern of justifying reimbursement recommendations, as revealed primarily in terms of budget impact and somewhat less so for cost-effectiveness rationales.

Keywords: Reimbursement recommendations; AHTAPol; HTA agencies; AOTMiT (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-023-01655-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:25:y:2024:i:8:d:10.1007_s10198-023-01655-x

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-023-01655-x

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().